{
    "info": {
        "nct_id": "NCT04570423",
        "official_title": "A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy",
        "inclusion_criteria": "1. Participant must have a pathologic/histologic confirmed newly diagnosed/relapsed/recurrent solid tumor or lymphoma without bone marrow involvement.\n2. Participant must be a candidate to receive myelosuppressive chemotherapy, with a febrile neutropenia rate of at least 20% as outlined in the National Comprehensive Cancer Network (NCCN) guidelines.\n3. Participant has adequate hematological, renal, and hepatic function.\n4. Participant must have an echocardiogram (ECHO) or multigated acquisition (MUGA) within 14 days of Screening if receiving a cardiotoxic therapy and have a cardiac ejection fraction of >50%.\n5. Participant must have a lumbar puncture, if clinically indicated, to rule out central nervous system (CNS) involvement within 14 days of study entry.\n6. Participant has a Karnofsky performance level ≥50% for patients ≥16 years of age or a Lansky performance level ≥50 for children <16 years of age.\nHealthy volunteers allowed\nMust have minimum age of 1 Month\nMust have maximum age of 17 Years",
        "exclusion_criteria": "1. Participant has an uncontrollable infection, has an underlying medical condition, and/or another serious illness that would impair the ability of the participant to receive protocol-specified treatment.\n2. Participant has had previous exposure to filgrastim (within 7 days), pegfilgrastim (within 14 days), or other granulocyte colony stimulating factor (G-CSF) products in clinical development within 2 weeks prior to the administration of study drug (eflapegrastim)\n3. Participant requires concurrent radiation therapy specifically in Cycle 1.\n4. Participant has had prior bone marrow or hematopoietic stem cell transplant and/or has concurrent bone marrow involvement in their malignancy, including leukemia.\n5. Participant has had spinal radiation therapy within 30 days prior to study enrollment.\n6. Participant has used any investigational drugs, biologics or devices within 30 days prior to study treatment or plans to use any of these during the study.\n7. Participant has a known sensitivity or previous reactions to any of the G-CSF products.\n8. Participant with active CNS disease.\n9. Participant has not recovered from previous treatment adverse events to ≤Grade 1.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. Participant must be a candidate to receive myelosuppressive chemotherapy, with a febrile neutropenia rate of at least 20% as outlined in the National Comprehensive Cancer Network (NCCN) guidelines.",
            "criterions": [
                {
                    "exact_snippets": "Participant must be a candidate to receive myelosuppressive chemotherapy",
                    "criterion": "candidate for myelosuppressive chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "febrile neutropenia rate of at least 20% as outlined in the National Comprehensive Cancer Network (NCCN) guidelines",
                    "criterion": "febrile neutropenia rate of planned chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "rate",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 17 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 17 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 17,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participant must have a pathologic/histologic confirmed newly diagnosed/relapsed/recurrent solid tumor or lymphoma without bone marrow involvement.",
            "criterions": [
                {
                    "exact_snippets": "pathologic/histologic confirmed newly diagnosed/relapsed/recurrent solid tumor or lymphoma",
                    "criterion": "solid tumor or lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation",
                            "expected_value": "pathologic/histologic confirmed"
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "newly diagnosed",
                                "relapsed",
                                "recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "without bone marrow involvement",
                    "criterion": "bone marrow involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Participant must have a lumbar puncture, if clinically indicated, to rule out central nervous system (CNS) involvement within 14 days of study entry.",
            "criterions": [
                {
                    "exact_snippets": "Participant must have a lumbar puncture, if clinically indicated",
                    "criterion": "lumbar puncture",
                    "requirements": [
                        {
                            "requirement_type": "procedure performed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical indication",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "to rule out central nervous system (CNS) involvement",
                    "criterion": "central nervous system (CNS) involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "within 14 days of study entry",
                    "criterion": "lumbar puncture timing",
                    "requirements": [
                        {
                            "requirement_type": "time before study entry",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 1 Month",
            "criterions": [
                {
                    "exact_snippets": "Must have minimum age of 1 Month",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "Month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Participant has a Karnofsky performance level ≥50% for patients ≥16 years of age or a Lansky performance level ≥50 for children <16 years of age.",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky performance level ≥50% for patients ≥16 years of age",
                    "criterion": "Karnofsky performance level",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Lansky performance level ≥50 for children <16 years of age",
                    "criterion": "Lansky performance level",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participant has adequate hematological, renal, and hepatic function.",
            "criterions": [
                {
                    "exact_snippets": "adequate hematological ... function",
                    "criterion": "hematological function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Participant must have an echocardiogram (ECHO) or multigated acquisition (MUGA) within 14 days of Screening if receiving a cardiotoxic therapy and have a cardiac ejection fraction of >50%.",
            "criterions": [
                {
                    "exact_snippets": "echocardiogram (ECHO) or multigated acquisition (MUGA) within 14 days of Screening if receiving a cardiotoxic therapy",
                    "criterion": "echocardiogram (ECHO) or multigated acquisition (MUGA)",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_days_of_screening",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "conditional_on_cardiotoxic_therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac ejection fraction of >50%",
                    "criterion": "cardiac ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "7. Participant has a known sensitivity or previous reactions to any of the G-CSF products.",
            "criterions": [
                {
                    "exact_snippets": "known sensitivity ... to any of the G-CSF products",
                    "criterion": "sensitivity to G-CSF products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previous reactions to any of the G-CSF products",
                    "criterion": "previous reactions to G-CSF products",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participant has an uncontrollable infection, has an underlying medical condition, and/or another serious illness that would impair the ability of the participant to receive protocol-specified treatment.",
            "criterions": [
                {
                    "exact_snippets": "uncontrollable infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "controllability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "underlying medical condition",
                    "criterion": "underlying medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "another serious illness that would impair the ability of the participant to receive protocol-specified treatment",
                    "criterion": "serious illness impairing ability to receive protocol-specified treatment",
                    "requirements": [
                        {
                            "requirement_type": "impact on treatment ability",
                            "expected_value": "impairs ability to receive protocol-specified treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Participant has had spinal radiation therapy within 30 days prior to study enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Participant has had spinal radiation therapy within 30 days prior to study enrollment.",
                    "criterion": "spinal radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to study enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Participant with active CNS disease.",
            "criterions": [
                {
                    "exact_snippets": "Participant with active CNS disease.",
                    "criterion": "CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Participant has had prior bone marrow or hematopoietic stem cell transplant and/or has concurrent bone marrow involvement in their malignancy, including leukemia.",
            "criterions": [
                {
                    "exact_snippets": "prior bone marrow or hematopoietic stem cell transplant",
                    "criterion": "history of bone marrow or hematopoietic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent bone marrow involvement in their malignancy, including leukemia",
                    "criterion": "concurrent bone marrow involvement in malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participant requires concurrent radiation therapy specifically in Cycle 1.",
            "criterions": [
                {
                    "exact_snippets": "Participant requires concurrent radiation therapy specifically in Cycle 1.",
                    "criterion": "concurrent radiation therapy in Cycle 1",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Participant has used any investigational drugs, biologics or devices within 30 days prior to study treatment or plans to use any of these during the study.",
            "criterions": [
                {
                    "exact_snippets": "Participant has used any investigational drugs, biologics or devices within 30 days prior to study treatment",
                    "criterion": "use of investigational drugs, biologics or devices",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "prior to study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "plans to use any of these during the study",
                    "criterion": "planned use of investigational drugs, biologics or devices",
                    "requirements": [
                        {
                            "requirement_type": "planned use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "during the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Participant has not recovered from previous treatment adverse events to ≤Grade 1.",
            "criterions": [
                {
                    "exact_snippets": "Participant has not recovered from previous treatment adverse events to ≤Grade 1.",
                    "criterion": "recovery from previous treatment adverse events",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "2. Participant has had previous exposure to filgrastim (within 7 days), pegfilgrastim (within 14 days), or other granulocyte colony stimulating factor (G-CSF) products in clinical development within 2 weeks prior to the administration of study drug (eflapegrastim)",
            "criterions": [
                {
                    "exact_snippets": "previous exposure to filgrastim (within 7 days)",
                    "criterion": "previous exposure to filgrastim",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "previous exposure to pegfilgrastim (within 14 days)",
                    "criterion": "previous exposure to pegfilgrastim",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "previous exposure to ... other granulocyte colony stimulating factor (G-CSF) products in clinical development within 2 weeks",
                    "criterion": "previous exposure to other granulocyte colony stimulating factor (G-CSF) products in clinical development",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}